Main Article Content

Abstract

A B S T R A C T
Anemia contributes to increased morbidity and mortality in chronic kidney disease
patients. The pathogenesis of anemia in these patients is multifactorial, but the
contribution of erythropoietin deficiency becomes greater as glomerular filtration
rate declines which related to decreased nephron mass. The current standard of
care includes supplemental iron, erythropoiesis-stimulating agents (ESA), and red
blood cell transfusions, although each has drawbacks. Lately, concern has arisen
following randomized clinical trials showing that higher hemoglobin targets and/or
high ESA doses may cause significant harm including increasing cardiovascular and
thrombotic events, and even death. Recent experimental and clinical studies show
the promising efficacy of hypoxia inducible factor (HIF) stabilizer which stimulates
endogenous erythropoietin production and enhance iron availability.

Keywords

Chronic Kidney Disease Anemia Erythropoiesis-stimulating Agents Hypoxia Inducible Factor Stabilizer.

Article Details

How to Cite
Emilia, & Zulkhair Ali. (2021). Anemia in Chronic Kidney Disease : Role of Hypoxia Inducible Factor Stabilizer. Bioscientia Medicina : Journal of Biomedicine and Translational Research, 5(3), 395-400. https://doi.org/10.32539/bsm.v5i3.234